NetworkNewsBreaks – VIVO Cannabis Inc. (TSX.V: V
Post# of 111
(Total Views: 204)
Posted On: 09/17/2019 4:10:35 PM
NetworkNewsBreaks – VIVO Cannabis Inc. (TSX.V: VIVO) (OTCQX: VVCIF) Announces Partnership with Linneo Health to Supply Medical Cannabis in Europe
VIVO Cannabis Inc. (TSX.V: VIVO) (OTCQX: VVCIF) this morning announced that it has engaged with Linneo Health S.L., a subsidiary of Alcaliber S.A., to be its European medical cannabis supply partner. A European leader in the pharmaceutical cannabis industry, Linneo Health recently received its EU-GMP (“Good Manufacturing Practices”) certification from the Spanish regulatory authorities. According to the update, the multi-year agreement includes increasing supply volumes as VIVO expands in the European medical market. “Our partnership with Linneo Health is part of our strategic priority to accelerate international market growth,” VIVO CEO Barry Fishman said in the news release. “We are excited to have an EU-GMP certified source of medical cannabis located within Europe. Through this partnership, we expect to be able to supply the European high-growth market with premium medical cannabis products and services. Our European based supply will allow VIVO to contribute to addressing the unmet medical needs of patients in Germany, which is one of our key target markets for international expansion.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
VIVO Cannabis Inc. (TSX.V: VIVO) (OTCQX: VVCIF) this morning announced that it has engaged with Linneo Health S.L., a subsidiary of Alcaliber S.A., to be its European medical cannabis supply partner. A European leader in the pharmaceutical cannabis industry, Linneo Health recently received its EU-GMP (“Good Manufacturing Practices”) certification from the Spanish regulatory authorities. According to the update, the multi-year agreement includes increasing supply volumes as VIVO expands in the European medical market. “Our partnership with Linneo Health is part of our strategic priority to accelerate international market growth,” VIVO CEO Barry Fishman said in the news release. “We are excited to have an EU-GMP certified source of medical cannabis located within Europe. Through this partnership, we expect to be able to supply the European high-growth market with premium medical cannabis products and services. Our European based supply will allow VIVO to contribute to addressing the unmet medical needs of patients in Germany, which is one of our key target markets for international expansion.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)VIVO Cannabis Inc. (VVCIF) Stock Research Links
Scroll down for more posts ▼